Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genakumab in active systemic juvenile idiopathic arthritis
CTR20231845Phase 3Active
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of genakumab in systemic juvenile idiopathic arthritis (SJIA), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Started Feb 2024; status: active.
02
Drugs
genakumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on CTR20231845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231845.